Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Abstract
Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine-responsive breast cancer. Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties.

This publication has 44 references indexed in Scilit: